Article thumbnail

Molecular Design, Functional Characterization and Structural Basis of a Protein Inhibitor Against the HIV-1 Pathogenicity Factor Nef

By Sebastian Breuer, Simone I. Schievink, Antje Schulte, Wulf Blankenfeldt, Oliver T. Fackler and Matthias Geyer


Increased spread of HIV-1 and rapid emergence of drug resistance warrants development of novel antiviral strategies. Nef, a critical viral pathogenicity factor that interacts with host cell factors but lacks enzymatic activity, is not targeted by current antiviral measures. Here we inhibit Nef function by simultaneously blocking several highly conserved protein interaction surfaces. This strategy, referred to as “wrapping Nef”, is based on structure-function analyses that led to the identification of four target sites: (i) SH3 domain interaction, (ii) interference with protein transport processes, (iii) CD4 binding and (iv) targeting to lipid membranes. Screening combinations of Nef-interacting domains, we developed a series of small Nef interacting proteins (NIs) composed of an SH3 domain optimized for binding to Nef, fused to a sequence motif of the CD4 cytoplasmic tail and combined with a prenylation signal for membrane association. NIs bind to Nef in the low nM affinity range, associate with Nef in human cells and specifically interfere with key biological activities of Nef. Structure determination of the Nef-inhibitor complex reveals the molecular basis for binding specificity. These results establish Nef-NI interfaces as promising leads for the development of potent Nef inhibitors

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A cellpenetrating helical peptide as a potential HIV-1 inhibitor.
  2. (2005). A peptide inhibitor of HIV-1 assembly in vitro.
  3. (1995). A single amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein.
  4. (2003). A zinc clasp structure tethers Lck to T cell coreceptors CD4 and CD8.
  5. (1995). AURELIA, a program for computer-aided analysis of multidimensional NMR spectra.
  6. (2006). Biochemical indication for myristoylation-dependent conformational changes in HIV-1 Nef.
  7. (1995). Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.
  8. (2009). Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds.
  9. (2004). Coot: model-building tools for molecular graphics.
  10. (1996). Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain.
  11. (2009). Determinants in HIV-1 Nef for enhancement of virus replication and depletion of CD4+ T lymphocytes in human lymphoid tissue ex vivo.
  12. (1996). Discovering high-affinity ligands for proteins: SAR by NMR.
  13. (2001). Domain assembly, surface accessibility and sequence conservation in full length HIV-1 Nef.
  14. (2009). Effect of lentivirus encoding HIV-1 Nef-U3 shRNA on the function of HIVspecific memory CD4(+) T cells in patients with chronic HIV-1 infection.
  15. (2006). Functional characterization of HIV-1 Nef mutants in the context of viral infection.
  16. (1995). Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients.
  17. (2004). Guanidine alkaloid analogs as inhibitors of HIV-1 Nef interactions with p53, actin, and p56lck.
  18. (2007). HIV drug development: the next 25 years.
  19. (2009). HIV-1 Nef interferes with host cell motility by deregulation of Cofilin.
  20. (2010). HIV-1 Nef membrane association depends on charge, curvature, composition and sequence.
  21. (2009). HIV-1 Nef perturbs artificial membranes: investigation of the contribution of the myristoyl anchor.
  22. (2000). HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes.
  23. (2007). HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription.
  24. (2007). Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains.
  25. (2006). Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways.
  26. (1991). Importance of the nef gene for maintenance of high virus loads and for development of AIDS.
  27. (1999). Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.
  28. (2001). Inhibition of cellular functions of HIV-1 Nef by artificial SH3 domains.
  29. (1998). Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity.
  30. (2010). Interaction of propionylated and butyrylated histone H3 lysine marks with Brd4 bromodomains.
  31. (2007). Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1.
  32. (2007). Modulation of the immunological synapse: a key to HIV-1 pathogenesis?
  33. (2011). Nef does not inhibit F-actin remodelling and HIV-1 cell-cell transmission at the T lymphocyte virological synapse.
  34. (1998). Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice.
  35. (1995). Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.
  36. (1999). Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking.
  37. (2006). Nefmediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1.
  38. (2007). Phaser crystallographic software.
  39. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution.Acta Crystallogr.
  40. (2007). Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein.
  41. (2010). Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication.
  42. (1997). Refined solution structure and backbone dynamics of HIV-1 Nef.
  43. (1997). Refinement of macromolecular structures by the maximum-likelihood method.
  44. (2008). Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein.
  45. (2005). Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef.
  46. (2010). Role of HIV-1 Nef protein for virus replication in vitro.
  47. (2008). Role of Nef in primate lentiviral immunopathogenesis.
  48. (1998). RT loop flexibility enhances the specificity of Src family SH3 domains for HIV-1 Nef.
  49. (1999). SH3 domains with high affinity and engineered ligand specificities targeted to HIV-1 Nef.
  50. (2010). Small molecule inhibition of HIV-1-induced MHC-I down-regulation identifies a temporally regulated switch in Nef action.
  51. (2004). Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.
  52. (2002). Structural basis for acidic-cluster-dileucine sorting-signal recognition by VHS domains.
  53. (2002). Structural basis for recognition of acidic-cluster dileucine sequence by GGA1.
  54. (2001). Structure–function relationships in HIV-1 Nef.
  55. (2002). Subunit H of the V-ATPase binds to the medium chain of adaptor protein complex 2 and connects Nef to the endocytic machinery.
  56. (2002). Subunit H of the V-ATPase involved in endocytosis shows homology to beta-adaptins.
  57. (2010). Tetherin: holding on and letting go.
  58. (1997). The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling.
  59. (2005). The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor.
  60. (2005). The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell-surface CCR5 and CD4.
  61. (1996). The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase.
  62. (2009). Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.